Hay recursos disponibles en español. Explorar los recursos aquí »
For US Residents Only
Visit Health Care Professional Website
Patient Information (English | Español)
  Indication
Important Safety Information
Prescribing Information

Support and 
Resources

Smiling star sticker

SUPPORT TO RAVE ABOUT

Are there financial support options available for LIVMARLI?

Once you or your child are prescribed LIVMARLI, Mirum Access Plus (MAP) experts will help you navigate your insurance coverage and share financial support options that may help with out-of-pocket costs.

MAP Savings Program

MAP Savings Program

If you have commercial insurance and your insurance coverage for LIVMARLI is approved, the LIVMARLI Savings Program can offer:

Eligible patients may pay as little as $10 out of pocket per fill*

Mirum Patient Assistance Program (PAP)

Mirum Patient Assistance Program (PAP)

If you are uninsured or coverage is denied, the MAP team will determine your eligibility for the Mirum PAP. Mirum PAP allows you to:

Receive LIVMARLI at no cost to you for up to 1 calendar year*

*Subject to program terms and conditions.

Mirum Access Plus (MAP) logo

Enroll in Mirum Access Plus (MAP)

Receive support for every step of your LIVMARLI treatment.

Learn How to Enroll
background-section background-section
Support on the Go

SUPPORT ON THE GO

MAP Mobile

Designed for busy families on the go, MAP Mobile is a convenient text messaging service that makes communicating with MAP even easier. Enroll in MAP Mobile to:

  • Easily send MAP your insurance information to avoid delays
  • eSign documents to speed up processing
  • Follow the steps to getting your medication with the prescription tracker
  • Get reminders and customized notifications via text messaging
  • View the current status of your prescription
Mirum Access Plus (MAP) logo

Enroll in MAP Mobile

Sign Up
background-section background-section

LEAVE NO QUESTION UNASKED

Exclamation point sticker

Talking to your doctor

green-squiggly-line-horizontal green-squiggly-line-horizontal-mobile

Understanding Alagille syndrome and its treatment can be difficult. Speaking with your or your child's doctor can help make things easier.

When partnering with your doctor, conversation is key. It’s helpful to be open and honest so you can work as a team toward your treatment goals. Here are a few things to get the conversation started.

Tell your doctor

Tell your doctor

  • Itch severity
  • Treatment history
  • Any previous surgeries or transplants
  • Other conditions you or your child have
  • Medicines you or your child take
  • Specific goals related to health, treatment, and management of Alagille syndrome
Ask your doctor

Ask your doctor

  • Could LIVMARLI be an option for me or my child?
  • How will I know if LIVMARLI is working?
  • How is LIVMARLI taken?
  • What are the possible side effects? How can they be managed?
  • Can LIVMARLI be taken if someone has other health conditions or takes other medicines?
  • What support is available while taking LIVMARLI?
  • How do we get started?

Want to get started?

Print the Discussion Guide to bring to your next visit.

Download the Discussion Guide Descargar la Guía de Conversación
background-section background-section

Check it. Chart it. Discuss It.™

Get the Itch✓ app: An easy-to-use journal designed to help you and your doctor make sense of itch severity and more.

Itch✓ app on Apple iPhone

Get the Itch✓ app: An easy-to-use journal designed to help you and your doctor make sense of itch severity and more.

Download on the Apple App Store

Why use Itch✓?

  • See symptom patterns over time. View charts that are based on your observations
  • Stay organized with all entries in one place. Your observations will be categorized based on date and entry type
  • Share reports with your doctor. Be better prepared for your next doctor’s visit with a report generated by Itch✓. Reports include average itch severity, growth percentile data, photos, notes, and more

How does Itch✓ work?

Use Itch✓ twice a day—once in the morning and once in the evening—to create a journal of symptoms and observations. Get started by personalizing your profile, creating your child’s record, and logging your first journal entry.

What are some of the Itch✓ features?

  • Detailed charts that show your child’s itch severity and growth patterns against standard percentiles
  • Growth data that are generated when you log your child’s height and weight measurements every 30 days
  • Customizable reports for you to share with your doctor
  • Manage multiple records if you have more than one child with cholestatic liver disease
  • And more!
Download on the Apple App Store

Don’t have an iPhone®?

Get an Itch✓ printable journal that you can fill out to share with your doctor.

Download a Printable Journal Descargar un Diario Imprimible

Apple logo® and App Store® are registered trademarks of Apple Inc.

Itch✓ app on Apple iPhone
background-section background-section

YOU’RE QUITE RESOURCEFUL

Binoculars

LIVMARLI: Downloadable Resources

green-squiggly-line-horizontal green-squiggly-line-horizontal
Brochure

How LIVMARLI May Help

Whether you’re considering—or already preparing for—treatment, this brochure can help you learn more about LIVMARLI and how it works.

Download: English | Español

Tell your doctor

Talk to Your Doctor About LIVMARLI

Get ready for your next conversation with your doctor. This guide can help you talk about your treatment goals.

Download: English | Español

Mirum Access Plus (MAP): Downloadable Resources

Download icon

Steps to Getting Medication

Getting the medicine you need shouldn’t be difficult or confusing. This helpful guide highlights the steps to getting LIVMARLI.

Download: English | Español

Download icon

All About MAP

A program designed to be there for you when and where you need it, MAP will provide you with education and support to help you get started and stay on track with treatment.

Download: English | Español

Download icon

MAP Consent Form

Enroll in the support program today by texting ENROLL to 1-833-MAP-4YOU (1-833-627-4968). Or, download and sign the MAP Consent Form to sign up.

Download: English | Español

Advocacy Groups

The Alagille Syndrome Alliance (ALGSA)

ALGSA is a non-profit organization with a goal of supporting the Alagille syndrome community by mobilizing resources, facilitating connections, promoting unity, and advocating a cure to inspire, empower, and enrich the lives of people affected by Alagille syndrome.

Visit the ALGSA

Yellow Alert

Yellow Alert is the Children’s Liver Disease Foundation’s awareness campaign promoting the early identification of liver disease in infants and their referral.

Visit Yellow Alert

Children’s Liver Association for Support Services (CLASS)

CLASS is an all-volunteer group helping children affected with liver diseases by addressing the emotional, educational, and financial needs of families.

Visit CLASS

National Organization for Rare Disorders (NORD)

NORD is a patient advocacy organization dedicated to individuals with rare diseases and the organizations that serve them. NORD is committed to the identification, treatment, and cure of rare disorders through programs of education, advocacy, research, and patient services.

Visit NORD

Indication

LIVMARLI is a prescription medicine used to treat cholestatic pruritus (itch) in patients with Alagille syndrome 1 year of age and older. It is not known if LIVMARLI is safe and effective in children under 1 year of age or in adults 65 years and older.

Important Safety Information

What are the possible side effects 
of LIVMARLI?

LIVMARLI can cause serious side effects, including:

Changes in liver tests. Changes in certain liver tests are common in patients with Alagille syndrome but may worsen during treatment with LIVMARLI. These changes may be a sign of liver injury and can be serious. Your health care provider should do blood tests before starting and during treatment to check your liver function. Tell your health care provider right away if you get any signs or symptoms of liver problems, including:

  • nausea or vomiting
  • skin or the white part of the eye turns yellow
  • dark or brown urine
  • pain on the right side of the stomach (abdomen)
  • loss of appetite

Stomach and intestinal (gastrointestinal) problems. LIVMARLI can cause stomach and intestinal problems, including diarrhea, stomach pain, and vomiting during treatment. Tell your health care provider right away if you have any of these symptoms more often or more severely than normal for you.

A condition called Fat-Soluble Vitamin (FSV) Deficiency caused by low levels of certain vitamins (vitamins A, D, E, and K) stored in body fat. FSV deficiency is common in patients with Alagille syndrome but may worsen during treatment. Your health care provider should do blood tests before starting and during treatment.

Other common side effects reported during treatment were bone fractures and gastrointestinal bleeding.

Tell your health care provider about all medicines that you take. LIVMARLI may affect the way some other medicines work, and some other medicines may affect the way LIVMARLI works. If you take a medicine that lowers cholesterol by binding bile acids, such as cholestyramine, colesevelam, or colestipol, take it at least 4 hours before or 4 hours after you take LIVMARLI.

LIVMARLI is taken by mouth, 1 time each day, 30 minutes before the first meal of the day. Be sure to use the provided oral dosing dispenser to accurately measure the dose of medicine.

These are not all of the possible side effects of LIVMARLI. Call your health care provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please see Patient Information: English | Español

expand btn collapse btn

Indication

LIVMARLI is a prescription medicine used to treat cholestatic pruritus (itch) in patients with Alagille syndrome 1 year of age and older. It is not known if LIVMARLI is safe and effective in children under 1 year of age or in adults 65 years and older.

Important Safety Information

What are the possible side effects 
of LIVMARLI?

LIVMARLI can cause serious side effects, including:

Changes in liver tests. Changes in certain liver tests are common in patients with Alagille syndrome but may worsen during treatment with LIVMARLI. These changes may be a sign of liver injury and can be serious. Your health care provider should do blood tests before starting and during treatment to check your liver function. Tell your health care provider right away if you get any signs or symptoms of liver problems, including:

  • nausea or vomiting
  • skin or the white part of the eye turns yellow
  • dark or brown urine
  • pain on the right side of the stomach (abdomen)
  • loss of appetite

Stomach and intestinal (gastrointestinal) problems. LIVMARLI can cause stomach and intestinal problems, including diarrhea, stomach pain, and vomiting during treatment. Tell your health care provider right away if you have any of these symptoms more often or more severely than normal for you.

A condition called Fat-Soluble Vitamin (FSV) Deficiency caused by low levels of certain vitamins (vitamins A, D, E, and K) stored in body fat. FSV deficiency is common in patients with Alagille syndrome but may worsen during treatment. Your health care provider should do blood tests before starting and during treatment.

Other common side effects reported during treatment were bone fractures and gastrointestinal bleeding.

Tell your health care provider about all medicines that you take. LIVMARLI may affect the way some other medicines work, and some other medicines may affect the way LIVMARLI works. If you take a medicine that lowers cholesterol by binding bile acids, such as cholestyramine, colesevelam, or colestipol, take it at least 4 hours before or 4 hours after you take LIVMARLI.

LIVMARLI is taken by mouth, 1 time each day, 30 minutes before the first meal of the day. Be sure to use the provided oral dosing dispenser to accurately measure the dose of medicine.

These are not all of the possible side effects of LIVMARLI. Call your health care provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please see Patient Information: English | Español